Sonoma Pharmaceuticals EBIT

The latest EBIT for SNOA is $-2.1M as of June 2026. That compares with $-3.7M in the prior-year period — up 43.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Sonoma Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, SNOA's EBIT moved from $-3.7M to $-2.1M — a 43.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sonoma Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, SNOA currently prints $-2.1M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Sonoma Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-2.1M for SNOA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting SNOA's EBIT ($-2.1M), review year-over-year change from $-3.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.